Key facts
- Ciliatech’s last known valuation is $12.9M (Feb 2025).
- It has raised $7.2M.
- Notable investors include Bpifrance, UI Investissement, BNP Paribas Développement, Bernard Chauvin, Kreaxi.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Ciliatech
- ·The full record, as it builds
Funding rounds
No funding rounds for Ciliatech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ciliatech
Developer of an intraocular implant designed for the treatment of glaucoma. The company's implant, which is a cilio-ccleral interpositioning device, effectively reduces intraocular pressure without penetrating the anterior chamber or creating subconjunctival filtration, enabling eye surgeons to overcome the serious complications and shortcomings of glaucoma surgical techniques.
- Sector
- Healthcare
- HQ
- Chavanod, France
- Founded
- 2017
- Employees
- 20
- Website
- cilia.tech/
- Ownership
- Privately Held (backing)
Ciliatech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ciliatech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ciliatech in its N-PORT filings yet. We sweep new filings monthly.